F-1: Psyence Biomedical Registers 104.9 Million Shares for Resale, Including White Lion Commitment

Psyence Biomedical files an F-1 registration statement for the potential resale of up to 104.9 million common shares by selling securityholders, including shares related to the White Lion Capital agreement and PGI swap agreements.

Summary

• Psyence Biomedical has filed a registration statement for the potential resale of up to 104,921,314 common shares.
• The shares include up to 100,000,000 commitment shares issuable to White Lion Capital under a purchase agreement.
• Also included are 2,921,314 shares issued to Psyence Group Inc. (PGI) under swap agreements and 2,000,000 shares issued to PGI under the Psylabs Purchase Agreement.
• White Lion has the option to purchase up to $25 million worth of common shares, subject to certain limitations.
• The company will not receive any proceeds from the resale of shares by the selling securityholders, but may receive up to $21,638,500 from the sale of shares to White Lion.
• The company is registering these shares to comply with agreements with White Lion and PGI.
• The company's common shares trade on the Nasdaq Global Market under the symbol PBM.
• The company is an emerging growth company and a foreign private issuer, which allows for reduced public company reporting requirements.

Sentiment

Score: 4

Explanation: The document is primarily factual, but the potential for share dilution and the company's low stock price suggest a cautious outlook.

Positives

• The registration allows Psyence Biomedical to fulfill its obligations under agreements with White Lion Capital and PGI.
• The company may receive up to $21.6 million in gross proceeds from sales to White Lion, which can be used for general corporate purposes.
• Being an emerging growth company and a foreign private issuer allows for reduced reporting requirements, potentially saving costs and resources.

Negatives

• The potential sale of a large number of shares could depress the market price of the company's common shares.
• The company will not receive any proceeds from the resale of shares by the selling securityholders other than White Lion.
• The company's stock price was $0.09 on October 29, 2024, indicating a low valuation.

Risks

• The potential sale of a large number of shares could depress the market price of the company's common shares and impair the ability to raise capital.
• The company is dependent on White Lion purchasing shares to receive proceeds.
• The company is subject to risks and uncertainties, including those highlighted in the section entitled Risk Factors, that represent challenges that we face in connection with the successful implementation of our strategy and the growth of our business.

Future Outlook

The company may receive up to $21,638,500 from the sale of Common Shares to White Lion pursuant to the White Lion Purchase Agreement after the date of this prospectus. The actual proceeds from White Lion may be less than this amount, depending on the number of Common Shares sold and the price at which the Common Shares are sold.

Industry Context

The announcement reflects the ongoing trend of biotechnology companies utilizing equity lines of credit to secure funding for research and development activities, while also highlighting the potential risks associated with significant share dilution.

Comparison to Industry Standards

• The use of equity lines of credit is a common practice among small-cap biotechnology companies, but the potential for significant dilution is a concern for investors.
• Comparable companies such as Atai Life Sciences (ATAI) and Compass Pathways (CMPS) are also involved in psychedelic drug development, but their financial structures and funding strategies may differ.

Related Party Transactions

• On January 25, 2024, the Corporation issued an unsecured convertible promissory note to PGI (the PGI Note), in the principal amount of $1,610,657, which is equal to the total amount owed to PGI in connection with loans PGI had previously made to the Corporation.
• Effective September 30, 2024, the Corporation entered into a swap agreement with the Sponsor and effective September 30, 2024 and October 25, 2024 respectively, the Corporation entered into two swap agreements with PGI (the Swap Agreements).
• Pursuant to the Swap Agreements, the Company has agreed to issue to the Sponsor and PGI 3,231,002 Common Shares and 2,921,314 Common Shares, respectively, at a price of $0.50 per Common Share.

Stakeholder Impact

• Shareholders may experience dilution due to the potential issuance of a large number of common shares.
• The company's ability to raise capital in the future could be affected by the potential for share price depression.

Next Steps

• The Selling Securityholders may sell or otherwise dispose of the Common Shares described in this prospectus in a number of different ways and at varying prices.
• The company intends to actively monitor its MVLS and MVPHS and will evaluate available options to regain compliance with the Nasdaq continued listing standards.

Key Dates

Keywords

common shares, registration statement, White Lion Capital, Psyence Biomedical, resale, PGI, Psylabs, equity, financing, Nasdaq